New EQA Programme is now available
We are proud to introduce our new external quality assessment programme for 2021. The new product catalogue includes 11 interesting new EQA programs and a pre-announcement of 7 pilot programs. Already 6500 clinical laboratories and point-of-care testing sites globally have chosen Labquality as their primary EQA provider. Labquality provides clinically relevant EQA programs to support continuous quality improvements for the benefit of patients.
Highlights
Covid-19 diagnostics
SARS-CoV-2 nucleic acid detection and SARS-CoV-2 antibodies schemes were introduced as pilots already in the summer 2020. Now the design and specifications of the programs have been finalized to support all types of laboratories and testing systems. Wide international peer groups guarantee valuable information for the participants. We will add one more scheme, SARS-CoV-2 antigens to complete our program for Covid-19 diagnostics. The antigen detection scheme will be introduced as a pilot round later this fall.
- 5677 SARS-CoV-2, antibodies
- 5676 SARS-CoV-2, nucleic acid detection
- Pilot SARS-CoV-2, antigen detection (preliminary scheduled for November 2020)
Urine bacterial screening with automated analyzers
Bacterial particle count with automated analyzers has been missing EQA for many years. Now it finally seems that we have found suitable sample materials to introduce an EQA program for this purpose. However the first round of 2021 is still launched as a pilot round to make the final validation.
- 3170 Urine bacterial screening with automated analyzers
Other new programs
- 2525 5-Hydroxyindoleacetic Acid (5HIAA)
- 5850 Brucella, antibodies
- 2733 Erythrocyte sedimentation rate iSED
- 4340 INR, LabPad, POCT
- 5462 Malaria screening, Giemsa stain
- 5463 Malaria screening, MGG stain
- 5673 Respiratory adenovirus, antigen detection
- 5636 Zika virus, antibodies
More information
Share this article
